Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover…
$306.20+2.41%
报价 2026-11-06
市值
$6.12B
EV
$4.27B
PE (TTM)
31.8x
预期 PE (FY2026)
32.2x
52 周区间距高点 -5.1%
$181.65$322.75
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-07不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| LGNDLigand Pharmaceuticals, Inc. | $6.12B | +2.4% | +8.0% | 97.5% | 31.8x | 21.8x | 124.3x | |
| PRAXPraxis Precision Medicines, Inc. | $7.75B | +5.7% | +1400.0% | 0% | – | – | – | |
| BLTEBelite Bio, Inc | $6.2B | +7.7% | – | 0% | – | – | – | |
| MIRMMirum Pharmaceuticals, Inc. | $6.09B | +0.2% | +30.9% | 81.7% | – | – | – | |
| ACADACADIA Pharmaceuticals Inc. | $3.66B | -0.0% | +14.8% | 91.7% | 9.1x | 26.3x | 34.6x | |
| VKTXViking Therapeutics, Inc. | $3.42B | +4.1% | +380.0% | 0% | – | – | – | |
| DYNDyne Therapeutics, Inc. | $3.37B | +4.1% | +42.9% | 0% | – | – | – | |
| ADMAADMA Biologics, Inc. | $2.85B | -3.6% | +11.7% | 68.5% | 16.7x | 12.0x | 22.3x | |
| NAMSNewAmsterdam Pharma Company N.V. | $2.26B | +0.1% | – | 99.7% | – | – | – | |
| 同行中位数 | – | – | +36.9% | 34.3% | 12.9x | 19.2x | 28.4x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。